AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

DISEASE CHARACTERISTICS:

Histologically or cytologically confirmed advanced solid tumors or lymphoma
Must have measurable disease outside a previously irradiated field OR regrowth of tumor within a previously irradiated field
Must be a candidate for gemcitabine hydrochloride treatment, in the opinion of the investigator
No untreated or symptomatic brain metastases
No tumors with direct bowel invasion
No other hematological malignancies
No non-small cell lung cancer of squamous cell histology or large central tumor (lesions ≥ 3 cm and located adjacent to or within the hilum or mediastinum)

PATIENT CHARACTERISTICS:

ECOG performance status 0-2
Not pregnant
No nursing during and for 6 months after completion of study treatment
Fertile patients must use effective contraception during and for 6 months after completion of study treatment
Negative pregnancy test
Able to swallow oral medication
Absolute neutrophil count ≥ 1,500/mm^3
Platelet count ≥ 100,000/mm^3
Hemoglobin ≥ 9 g/dL
Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 40 mL/min
Albumin-adjusted calcium ≥ 8 mg/dL
Urine protein < 30 mg/dL by urinalysis or < 1+ by dipstick OR < 500 mg by 24-hour urine collection
AST or ALT ≤ 2.5 times upper limit of normal (ULN) (5.0 times ULN in the presence of liver metastasis or primary hepatic neoplasm)
Bilirubin ≤ 2 times ULN
PT ≤ 2.0
INR or PTT ≤ 1.5 times ULN
Systolic blood pressure (BP) ≤ 145 mm Hg and diastolic BP ≤ 85 mm Hg (stable antihypertensive medication allowed)
No myocardial infraction within the past year
No arterial thrombosis or deep vein thrombosis within the past year
No unstable angina
No congestive heart failure
No New York Heart Association class III-IV cardiac disease
No other unstable or uncontrolled disease or condition relating to or impacting cardiac function
No HIV positivity
No other condition that would preclude study participation, compliance, or follow-up assessments

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
No prior enrollment into this study
At least 1 month since prior investigational device or drug trial
At least 1 month since prior major surgical procedure
At least 3 weeks since prior systemic chemotherapy
At least 2 weeks since prior radiotherapy
At least 2 weeks since prior rifampin or phenobarbital

At least 1 week since prior treatment with any of the following:

Ketoconazole
Itraconazole
Clarithromycin
Erythromycin
Cyclosporine or tacrolimus
Nefazodone
Herbal medications containing Hypericum perforatum (St. John's wort)

At least 1 week since prior and no concurrent warfarin

Concurrent prophylactic anticoagulation therapy (e.g., low-dose warfarin [≤ 2 mg/day] or low molecular weight heparin) for venous or arterial access devices allowed
No prior or concurrent kinase insert domain-receptor inhibitors

No concurrent chemotherapy, radiotherapy, hormone-directed cancer therapy, or tumor-directed antibody therapy

Gonadotropin releasing-hormone agonist therapy allowed
No concurrent interferon
No concurrent grapefruit juice or whole grapefruit
No other concurrent standard or investigational drugs or antitumor treatment, including c-kit, platelet-derived growth factor, vascular endothelial growth factor, or epidermal growth factor inhibitors
No elective surgery during or for 2 weeks after completion of the last dose of AMG 706